EBS News and Press, Emergent Biosolutions Inc. From 08/30/19

The following slide deck was published by Emergent BioSolutions Inc. in conjunction with this Read more ...

Emergent BioSolutions, Inc. (EBS) Q2 2019 Results Earnings Conference Call August 01, 2019, 05:00 PM ET Company Participants Bob Burrows - VP-IR Bob Kramer - President and CEO Rich Lindahl - CFO Doug White - SVP, Devices Business Unit Head Conference Call Participants Bra...

Emergent Biosolutions (NYSE: EBS ): Q2 Non-GAAP EPS of -$0.12 beats by $0.03 ; GAAP EPS of -$0.18 misses by $0.03 . More news on: Emergent BioSolutions Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Reaffirms full year 2019 financial forecast and operational goals Provides Q3 2019 revenue forecast of $245M-$275M GAITHERSBURG, Md., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the second quarter and six months ended June...

GAITHERSBURG, Md., July 30, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has exercised its first contract option valued at $261 million to procure doses of AV7909 (anthrax vaccine adsor...

GAITHERSBURG, Md., July 18, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, August 1, 2019 at 5:00 pm (Eastern Time) to discuss the financial results for the second quarter of 2019, recent business developments, revenue guidance for t...

GAITHERSBURG, Md., June 04, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced approval by the U.S. Food and Drug Administration (FDA) of the Prior Approval Supplement (PAS) submitted by the company for its oral cholera vaccine, Vaxchora ® (Cholera Vaccine, Li...

Emergent BioSolutions (NYSE: EBS ) has received a contract award of ~$535M over 10 years for the continued supply of Vaccinia Immune Globulin Intravenous (VIGIV) into the U.S. Strategic National Stockpile (SNS) in support of smallpox preparedness. More news on: Emergent BioSolutions Inc....

GAITHERSBURG, Md., June 03, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract award by the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) valued at approximately $535 m...

GAITHERSBURG, Md., May 20, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has successfully obtained marketing authorization for its oral typhoid vaccine Vivotif ® (Typhoid Vaccine Live Oral Ty21a) in five additional European Union Member States, i...